JP2003500450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003500450A5 JP2003500450A5 JP2000620961A JP2000620961A JP2003500450A5 JP 2003500450 A5 JP2003500450 A5 JP 2003500450A5 JP 2000620961 A JP2000620961 A JP 2000620961A JP 2000620961 A JP2000620961 A JP 2000620961A JP 2003500450 A5 JP2003500450 A5 JP 2003500450A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- compound
- hydrogen
- fluorine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 27
- 229910052731 fluorine Inorganic materials 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 125000006575 electron-withdrawing group Chemical group 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 3
- WMPTYRGXBUYONY-UHFFFAOYSA-N 2-chloroquinazoline Chemical compound C1=CC=CC2=NC(Cl)=NC=C21 WMPTYRGXBUYONY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/322,979 US6126917A (en) | 1999-06-01 | 1999-06-01 | Epidermal growth factor receptor binding compounds for positron emission tomography |
| US09/322,979 | 1999-06-01 | ||
| PCT/US2000/013749 WO2000072849A1 (en) | 1999-06-01 | 2000-05-19 | Novel epidermal growth factor receptor-binding compounds for positron emission tomography |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500450A JP2003500450A (ja) | 2003-01-07 |
| JP2003500450A5 true JP2003500450A5 (https=) | 2007-05-10 |
Family
ID=23257276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000620961A Pending JP2003500450A (ja) | 1999-06-01 | 2000-05-19 | 陽電子放射断層撮影法のための表皮成長因子受容体に結合する新規化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6126917A (https=) |
| EP (1) | EP1180034A4 (https=) |
| JP (1) | JP2003500450A (https=) |
| AU (1) | AU4857400A (https=) |
| CA (1) | CA2375826A1 (https=) |
| IL (1) | IL146805A0 (https=) |
| WO (1) | WO2000072849A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6585953B2 (en) * | 2000-09-07 | 2003-07-01 | Wisconsin Alumni Research Foundation | Synthesis of 17F labeled fluoroalkanes |
| US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| IL159270A0 (en) * | 2001-06-14 | 2004-06-01 | Yissum Res Dev Co | Non-myeloablative tolerogenic treatment with tyrphostins |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| JP2006515871A (ja) * | 2003-01-23 | 2006-06-08 | ティー．ケイ． シグナル リミテッド | 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用 |
| GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| JP2007500177A (ja) * | 2003-07-29 | 2007-01-11 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのピペリジルキナゾリン誘導体 |
| WO2005028469A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
| CN1882570B (zh) * | 2003-09-19 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
| KR20060100388A (ko) * | 2003-09-25 | 2006-09-20 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| NO20035681D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av lungekreft |
| NO20035682D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av ösofagkreft og Barretts ösofag |
| MX2007010399A (es) * | 2005-02-26 | 2007-09-25 | Astrazeneca Ab | Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina. |
| AU2006288716A1 (en) * | 2005-09-06 | 2007-03-15 | T.K. Signal Ltd. | Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal growth factor receptor tyrosine kinase |
| JP4945133B2 (ja) * | 2006-01-19 | 2012-06-06 | 富士フイルムＲｉファーマ株式会社 | ４−フェノキシキナゾリン誘導体放射性化合物 |
| EP1921070A1 (de) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| EP2118075A1 (de) * | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| FR2926079B1 (fr) * | 2008-01-03 | 2012-12-28 | Commissariat Energie Atomique | Procede de preparation d'un derive de purine marque, ledit derive et ses utilisations |
| CA2711582A1 (en) * | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof |
| EP2303276B1 (en) | 2008-05-13 | 2013-11-13 | AstraZeneca AB | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline |
| CA2733153C (en) * | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| SG173014A1 (en) | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US8753605B2 (en) | 2010-08-31 | 2014-06-17 | The Board Of Trustees Of The Leland Stanford Junior University | Imaging probes, methods of making imaging probes, and methods of imaging |
| CN103254140B (zh) * | 2012-02-17 | 2016-02-17 | 北京师范大学 | 新型18f标记取代喹唑啉类化合物及其制备方法和肿瘤pet显像应用 |
| WO2017122205A1 (en) | 2016-01-13 | 2017-07-20 | Hadasit Medical Research Services And Development Ltd. | Radiolabeled erlotinib analogs and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57144266A (en) * | 1981-03-04 | 1982-09-06 | Sankyo Co Ltd | 4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| JP2994165B2 (ja) * | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 |
| US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| BR9707495A (pt) * | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| CA2265630A1 (en) * | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| WO1999061428A1 (en) * | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
| US6172071B1 (en) * | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| US6313129B1 (en) * | 1998-08-21 | 2001-11-06 | Hughes Institute | Therapeutic compounds |
| EP1162974A1 (en) * | 1999-03-19 | 2001-12-19 | Parker Hughes Institute | Quinazoline formulations and therapeutic use thereof |
| US6258820B1 (en) * | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
-
1999
- 1999-06-01 US US09/322,979 patent/US6126917A/en not_active Expired - Lifetime
-
2000
- 2000-05-19 CA CA002375826A patent/CA2375826A1/en not_active Abandoned
- 2000-05-19 IL IL14680500A patent/IL146805A0/xx unknown
- 2000-05-19 JP JP2000620961A patent/JP2003500450A/ja active Pending
- 2000-05-19 AU AU48574/00A patent/AU4857400A/en not_active Abandoned
- 2000-05-19 WO PCT/US2000/013749 patent/WO2000072849A1/en not_active Ceased
- 2000-05-19 EP EP00930818A patent/EP1180034A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003500450A5 (https=) | ||
| MXPA04006003A (es) | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. | |
| JP2003532731A5 (https=) | ||
| JP2008509187A5 (https=) | ||
| JP2003531118A5 (https=) | ||
| ATE300941T1 (de) | Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung | |
| JP2002525323A5 (https=) | ||
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| JP2001515075A5 (https=) | ||
| LU90956I2 (fr) | Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique | |
| ID27531A (id) | Penggunaan senyawa untuk peningkatan aktivitas piruvat dehidrogenase | |
| JP2001526218A5 (https=) | ||
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| JP2003509349A5 (https=) | ||
| JP2002510633A5 (https=) | ||
| JP2002518502A5 (https=) | ||
| JP2019500355A5 (https=) | ||
| JP2002519425A5 (https=) | ||
| EP1175900A3 (en) | Use of growth hormone secretagogues for improvement of fucnctional health status | |
| JP2002506864A5 (https=) | ||
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| JP2003529597A5 (https=) | ||
| JP2004538314A5 (https=) | ||
| CA2392630A1 (en) | 2-amino-5,6-dihalo-3,4-dihydroquinazolines with blood platelet reducing properties |